Lack of fludeoxyglucose F 18 uptake in posttreatment positron emission tomography as a significant predictor of survival after subsequent surgery in multimodality treatment for patients with locally advanced esophageal squamous cell carcinoma

被引:55
作者
Higuchi, Ichirou [1 ]
Yasuda, Takushi [1 ]
Yano, Masahiko [1 ]
Doki, Yuichirou [1 ]
Miyata, Hiroshi [1 ]
Tatsumi, Mitsuaki [2 ]
Fukunaga, Hironori [1 ]
Takiguchi, Shuji [1 ]
Fujiwara, Yoshiyuki [1 ]
Hatazawa, Jun [2 ]
Monden, Morito [1 ]
机构
[1] Osaka Univ, Grad Sch Med, Dept Surg Gastroenterol, Osaka, Japan
[2] Osaka Univ, Grad Sch Med, Dept Nucl Med & Tracer Kinet, Osaka, Japan
关键词
D O I
10.1016/j.jtcvs.2008.02.016
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Patients with advanced esophageal squamous cell carcinoma receive neoadjuvant chemotherapy or chemoradiotherapy to improve survival, but benefits are observed only in those with histologic response. Positron emission tomography with fludeoxyglucose F 18 ( INN fludeoxyglucose [ (18)F]) detects accumulation of glucose analog in viable cancer cells. This study investigated the usefulness of positron emission tomography with fludeoxyglucose F 18 in assessment of response of advanced esophageal squamous cell carcinoma to neoadjuvant treatment to establish new criteria to predict postoperative long-term survival. Methods: Fifty patients with locally advanced esophageal squamous cell carcinoma who received neoadjuvant therapy ( chemotherapy 35, chemoradiotherapy 15) underwent positron emission tomography with fludeoxyglucose F 18 before surgical resection in evaluation of posttreatment maximum standardized uptake value, residual tumor size ( maximum square area of longitudinal axis), histologic response, and postoperative survival. Results: After treatment, uptake was not noted in 21 patients ( posttreatment maximum standardized uptake value <2.5, negative) but was detected in 29 (>= 2.5, positive). Residual tumor size ranged from 0 to 54.0 mm(2) for negative results and 55.0 to 676.0 mm(2) for positive, clearly distinguishing histologic major response from nonresponse. The negative group demonstrated significantly higher 5-year cause-specific survival ( 67.7%) and lower hematogenous recurrence ( 4.8%) than the 36.5% and 37.0% values in the positive group, ( P <.0042 and P = .0083, respectively). Univariate Cox regression analyses identified posttreatment maximum standardized uptake value ( cutoff 2.5) as the only preoperative prognostic factor ( P = .0071). Conclusion: Posttreatment positron emission tomography with fludeoxyglucose F 18 reliably predicted histologic response and postoperative survival in advanced esophageal squamous cell carcinoma. This tool could potentially be used to tailor optimal treatment according to individual responses.
引用
收藏
页码:205 / U114
页数:11
相关论文
共 32 条
[1]  
Arslan Nuri, 2002, Mol Imaging Biol, V4, P301, DOI 10.1016/S1536-1632(02)00011-2
[2]  
Brücher BLDM, 2001, ANN SURG, V233, P300
[3]   Whole body 18FDG-PET and the response of esophageal cancer to induction therapy:: Results of a prospective trial [J].
Downey, RJ ;
Akhurst, T ;
Ilson, D ;
Ginsberg, R ;
Bains, MS ;
Gonen, M ;
Koong, H ;
Gollub, M ;
Minsky, BD ;
Zakowski, M ;
Turnbull, A ;
Larson, SM ;
Rusch, V .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (03) :428-432
[4]   FDG-PET status following chemoradiotherapy provides high management impact and powerful prognostic stratification in oesophageal cancer [J].
Duong, Cuong P. ;
Hicks, Rodney J. ;
Weih, LeAnn ;
Drummond, Elizabeth ;
Leong, Trevor ;
Michael, Michael ;
Thomas, Robert J. S. .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2006, 33 (07) :770-778
[5]   Positron emission tomography for assessment of the response to induction radiochemotherapy in locally advanced oesophageal cancer [J].
Flamen, P ;
Van Cutsem, E ;
Lerut, A ;
Cambier, JP ;
Haustermans, K ;
Bormans, G ;
De Leyn, P ;
Van Raemdonck, D ;
De Wever, W ;
Ectors, N ;
Maes, A ;
Mortelmans, L .
ANNALS OF ONCOLOGY, 2002, 13 (03) :361-368
[6]  
Fukunaga H, 2002, INT J ONCOL, V20, P691
[7]   18FDG uptake during induction chemoradiation for oesophageal cancer fails to predict histomorphological tumour response [J].
Gillham, C. M. ;
Lucey, J. A. ;
Keogan, M. ;
Duffy, G. J. ;
Malik, V. ;
Raouf, A. A. ;
O'Byrne, K. ;
Hollywood, D. ;
Muldoon, C. ;
Reynolds, J. V. .
BRITISH JOURNAL OF CANCER, 2006, 95 (09) :1174-1179
[8]   Assessing chemotherapy response of squamous cell oesophageal carcinoma with spiral CT [J].
Griffith, JF ;
Chan, ACW ;
Chow, LTC ;
Leung, SF ;
Lam, YH ;
Liang, EY ;
Chung, SCS ;
Metreweli, C .
BRITISH JOURNAL OF RADIOLOGY, 1999, 72 (859) :678-684
[9]  
*JAP SOC ES DIS, 1999, GUID CLIN PATH STUD
[10]  
Jones DR, 1999, CANCER, V85, P1026, DOI 10.1002/(SICI)1097-0142(19990301)85:5<1026::AID-CNCR3>3.0.CO